Prices for 90% of drugs from the list of essential drugs will increase in the near future due to the adopted law on price indexation. Department of Science “Gazety.Ru” versed on how much prices can rise, as well as talks about whether Russia will not remain without drugs as a result of import substitution policy.
Strategy «Pharma 2020 », approved by the Ministry of Industry and Trade in October 2009, a plan for the development of the pharmaceutical industry in our country until 2020. The main goal of the program is “to ensure drug safety of the Russian Federation.” This means that the
in our country to 2020 should be launched production of not less than 85% of drugs from the list of vital and essential drugs (VED), while the share of domestic products in total consumption should reach 50% in value terms.
Since 2012 the VED list included 567 names of medicines, while in Russia made only 93 of them (representing 16.4% of the list). 267 medications (47.1%) were made by both domestic and foreign companies, and the remaining 207 (36.5%) were of foreign origin. The updated list of essential medicines, adopted in late December last year, already includes 608 names.
The representatives of the press service of the Ministry of Health reported “Gazeta.ru” that
at the moment in Russia produced 413 drugs (68% general list).
However, the question of whether or not these drugs are manufactured in our country is still open: at the moment there are no official documents that would clearly define what kind of production cycles the drug should be implemented on the territory of Russia to the drug considered domestic.
… Made in Russia?
At the moment, enough common situation is when the foreign company is only packed and packages produced overseas drugs in Russia. According to Elena Parhoninoy, deputy director of the office of the Hungarian pharmaceutical company “Gedeon Richter”, “if we use the criteria proposed by the Ministry of Industry in 2015, packaging and packing of medicines in Russia include drugs to local products.
Changes expected from the beginning of 2016, however, there is no clear understanding of what status will be determined by “local”.
What is ready to domestic pharmaceutical companies in a few months? This question has no clear answer. Vitaly Omel’yanovskii head Laboratory Technology Assessment in Health Care RANHiGS told “Gazeta.ru”, “The question of determining country of origin – a political solution to this issue can be treated differently. You can say that the domestic drugs are the only ones that have a wide production cycle in Russia, and we can say that domestic products – those that have some sort of Russian label. Who is in the interests of the developing market and the state there is a need to shift the percentage of the production cycle in Russia from zero to a hundred. Regarding the precise numbers there are big questions. ”
About the same trend and says Elena Parhonina. “Today there are more and more news about the transfer to Russia of a full cycle of production. But it is also necessary to understand that
there are drugs whose production in Russia can not be transferred because of their features. It is primarily a question of innovative products, indicated for the treatment of severe diseases such as cancer, rheumatoid arthritis, orphan disease (rare, most genetic diseases that affect a very small part of the population. – “Times» ), “- says the expert.
Change can not buy
The complexity of the organization of production of medicines in Russia lies in several factors. First of all, the replacement of foreign assets by domestic original in the short term would be simply impossible, since the creation and clinical trials of new drugs pharmaceutical giants spend huge amounts of money and decades. Why foreign manufacturers can not organize a full cycle of existing drugs in Russia?
«For foreign companies there is a risk that, if they give technology, then they already are no longer needed, so they will give technology only when the existence of the guarantee. While these forms of cooperation are not worked out, so it’s hard to believe that the company will come to us with absolute localization “- says Vitaly Omel’yanovskii.
Another problem is that the production of pharmaceutical substances in Russia is in very poor condition. A pharmaceutical substance – is the main component of the drug, which is an active ingredient or mixture of substances adequate purity, from which the medicine is manufactured. In the USSR, a substance produced, and they are not only used in the domestic market, but also exported abroad. As told to “Gazeta.ru” Aydar Ishmukhametov, director of the company for the production of bacterial and viral agents of the Institute of Poliomyelitis and Viral Encephalitis them. MP RAMS Chumakov, “after the collapse of the Soviet Union is a large-scale chemical industry was” killed “by the Chinese and Indian competitors, then do not hesitate to dump, and now – to raise prices. A separate issue – biotechnology. The production of such things as monoclonal antibodies (substances produced by immune cells and used to treat melanoma or breast cancer. – “Times» ), for example, will have to build from scratch – in the days of the Soviet Union and their in the world there was no one. ”
However, the main problem of the revival of the production of pharmaceutical substances – not a lack of personnel or technology. The global world market of substances already divided among several major manufacturers and, as claimed by Vitaly Omel’yanovskii “when Russia, with production and intellectual potential, trying to get into this market, it simply will not let go.” This means that
Russian market for substances will be very limited, so that domestic producers will not be able to lower prices below those at which supply their products to foreign companies, and as a result our substance will simply not competitive.
It is obvious that the effectiveness of the policy of import substitution drugs currently seems rather dubious. According to the Reports of DSM , dealing with the audit and analysis of the pharmaceutical market, when in April 2011 the share of Russian products in physical units in the domestic market was 61% in April 2015, he has not increased, but rather It decreased to 56%, while the average price per unit increased from 93.1 to 143.6 rubles. In sales value share of the Russian drug in the past four years has increased only slightly – from 24 to 25%. The company “Pharmstandard”, one of the largest pharmaceutical companies in our country, in 2011, together with the companies Sanofi-Aventis and Novartis among the top three by sales value, but in April 2015 the first three lines of the rating took foreign companies Novartis, Sanofi and Bayer.
Price pill too large
unchanged recent trend is the a steady decline in the share of low-cost (less 150 rubles. per pack) of drugs in the Russian market. This is due to the steady rise in prices: according to Rosstat, consumer prices for drugs at the beginning of 2015 grew and a half times faster than inflation, and in April of this year they grew by April 2014 was 25.8%. As stated in the Report Elena Balashova, a senior fellow at the Center of Higher School of Economics, for the same period, the retail price of VED increased by 8.9%.
The question of what will happen to the prices of medicines further, remains open. March 16, 2015, amendments to the federal law “On Circulation of Medicines”, providing for the producer price index for inflation and for Russian producers – even higher if the price increase is justified.
According to the forecasts of Elena Balashova, in the near future, the average price of medicines could increase by 16% compared to current levels, but it may relate to 90% of drugs from the list of VED.
«Forecasts at prices a bit high, but the trend will be such, – said Vitaly Omel’yanovskii. – The rise in prices is inevitable, and we must be prepared for their growth on foreign drugs and the domestic. “Kitchen” production of medicines rather closed, and the outside is very difficult to predict the exact figures of price increases. ” Agrees with him and Yuri Mochalin, Director of Corporate Affairs and Government Relations International pharmaceutical company “AstraZeneca Russia and Eurasia”, which, however, hopes that “the average price increase will be below the planned level of inflation”, as “the experience of the past years, not all manufacturers use the right to indexation of prices recorded. ”
Though experts and agree that the development and production of medicines in Russia face a number of serious problems, and the price will again increase, large foreign pharmaceutical companies are not going to leave the Russian market. The representative of the Hungarian company “Gedeon Richter” Elena Parhonina said: “We have a long, fruitful relationship with Russia, this market is strategically important for our company, so the question of whether to reduce its presence, not even worth it. But in general, due to the current political situation in the world and the complexities of the Russian economy pharmaceutical companies, of course, it had to review their activity.
Large companies conducted monitoring of business processes and analysis of the marketing activity, medium and small companies abandoned projects, and some even from entering the Russian market. Nevertheless, until the state of the pharmaceutical market is more stable than, say, the automotive market and the real estate market. ”
The economic sanctions on drug companies also do not apply, so in the near future Russia will not remain without drugs, though their availability and raises concerns. 
No comments:
Post a Comment